Henry ScheinWBO:HSIC +3.55%80 EBITDA Margin % is 8.02% as of Mar. 2026, which is 3% above its 10-year median of 7.77. GuruFocus rates WBO:HSIC with a GF Score™ of 80/100 and a GF Value™ of €73.69. The stock has 8 warning signs investors should review. Among 119 Medical Distribution companies, Henry Schein ranks better than 63.87% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Henry Schein's EBITDA for the
three
months ended in Mar. 2026 was €234 Mil. Henry Schein's Revenue for the
three
months ended in Mar. 2026 was €2,913 Mil. Therefore, Henry Schein's EBITDA margin for the quarter that ended in Mar. 2026 was 8.02%.
Henry Schein (WBO:HSIC) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Henry Schein EBITDA Margin % Related Terms
Henry Schein EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Henry Schein's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WBO:HSIC vs AHG, ACH, EDAP: EBITDA Margin % Comparison
For the Medical Distribution subindustry, Henry Schein's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Henry Schein EBITDA Margin % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Henry Schein's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Henry Schein's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Henry Schein (WBO:HSIC) has a EBITDA Margin % of 8.02% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Henry Schein and its competitors. This is near median its historical median of 7.77. Over the past decade, Henry Schein's EBITDA Margin % has ranged from 6.90 to 9.17. According to the industry distribution chart, Henry Schein ranks #43 out of 119 companies in the Medical Distribution industry, placing it in the top 36.1%.
Is Henry Schein's EBITDA Margin % too high?
Henry Schein's current EBITDA Margin % of 8.02% is near median its 10-year median of 7.77. Over the past 10 years, this metric has ranged from a low of 6.90 to a high of 9.17. The Medical Distribution industry median EBITDA Margin % is 4.31. Henry Schein's value of 8.02% is 86.1% above this industry median. Based on the distribution chart, Henry Schein ranks #43 out of 119 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, Henry Schein has a GF Score™ of 80/100, reflecting its overall financial health beyond just this single metric.
How does Henry Schein's EBITDA Margin % compare to AHG and ACH?
According to the Medical Distribution industry distribution chart, Henry Schein ranks #43 out of 119 companies for EBITDA Margin %. This puts Henry Schein in the upper half of its industry. The industry median EBITDA Margin % is 4.31. Henry Schein's value of 8.02% is 86.1% above this benchmark. Historically, Henry Schein's own EBITDA Margin % has ranged from 6.90 to 9.17 over the past decade. While the company's 10-year median is 7.77 vs. the industry median of 4.31, Henry Schein has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Distribution company?
The median EBITDA Margin % among Medical Distribution companies is 4.31, based on 119 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Henry Schein's current EBITDA Margin % of 8.02% is 86.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Henry Schein and its competitors. For the Medical Distribution industry, the median EBITDA Margin % is 4.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Henry Schein's current EBITDA Margin % is 8.02%, which is near median its own 10-year median of 7.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Henry Schein stock overvalued right now?
Henry Schein (WBO:HSIC) has a current EBITDA Margin % of 8.02%. The stock's GF Value™ is €73.69, compared to a current price of €73.00 — trading 0.9% below its estimated fair value. The current EBITDA Margin % is 8.02%, which is near median its 10-year median of 7.77 and 86.1% above the Medical Distribution industry median of 4.31. Henry Schein's overall GF Score™ is 80/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Henry Schein (WBO:HSIC), the current EBITDA Margin % is 8.02% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Henry Schein (WBO:HSIC) Overvalued in 2026?
Based on GuruFocus' analysis, Henry Schein stock appears to be undervalued.
The current stock price of €73.00 is trading 0.9% below its estimated GF Value™ of €73.69.
Key valuation signals for WBO:HSIC:
EBITDA Margin %: 8.02% (near median its 10-year median of 7.77)
GF Value™: €73.69 vs. price of €73.00 (0.9% below fair value)
Industry Position: 86.1% above the Medical Distribution median (#43 of 119)
No single metric tells the full story. See the WBO:HSIC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Henry Schein Inc is a solutions company for healthcare professionals. It offers healthcare equipment, products, and services to office-based dental and medical practitioners, as well as alternative sites of care. The company's reportable segments are: Global Distribution and Value-Added Services, Global Specialty Products, and Global Technology. It generates maximum revenue from the Global Distribution and Value-Added Services segment, which includes distribution to the dental and medical markets of national brand and corporate brand merchandise, as well as equipment and related technical services. This segment also includes value-added services such as financial services, continuing education services, consulting, and other practice services.
80GF Score
Get the complete analysis for WBO:HSIC
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WBO:HSIC has been successfully added to your 
